4:10 PM
May 16, 2019
 |  BC Extra  |  Clinical News

Roche, Bayer unveil brain tumor data for NTRK inhibitors ahead of ASCO

Efficacy data for two tissue-agnostic NTRK inhibitors from Roche and Bayer to treat primary and metastatic brain tumors were released in abstracts ahead of the American Society of Clinical Oncology meeting in Chicago.

Data from the Phase I/II STARTRK-NG trial of entrectinib from Roche (SIX:ROG; OTCQX:RHHBY) showed that the inhibitor of ROS1, TrkA, TrkB, TrkC and ALK led to one complete response (CR), three partial responses (PRs) and one unconfirmed PR among five evaluable pediatric patients with primary CNS tumors. STARTRK-NG enrolled pediatric patients with recurrent or refractory solid or primary CNS...

Read the full 444 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >